25
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in the presence of at least one of the two major clinical manifestations (i.e. thrombosis or pregnancy morbidity) of the syndrome. However, several other autoantibodies shown to be directed to other proteins or their complex with phospholipids have been proposed to be relevant to APS but their clinical utility and their diagnostic value remains elusive. This report summarizes the findings, conclusions and recommendations of the "APS Task Force 3-Laboratory Diagnostics and Trends" meeting that took place during the 14th International Congress on Antiphospholipid Antibodies (APLA 2013, September 18-21, Rio de Janeiro, RJ, Brazil).

          Related collections

          Most cited references139

          • Record: found
          • Abstract: not found
          • Article: not found

          GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            GRADE guidelines: 3. Rating the quality of evidence.

            This article introduces the approach of GRADE to rating quality of evidence. GRADE specifies four categories-high, moderate, low, and very low-that are applied to a body of evidence, not to individual studies. In the context of a systematic review, quality reflects our confidence that the estimates of the effect are correct. In the context of recommendations, quality reflects our confidence that the effect estimates are adequate to support a particular recommendation. Randomized trials begin as high-quality evidence, observational studies as low quality. "Quality" as used in GRADE means more than risk of bias and so may also be compromised by imprecision, inconsistency, indirectness of study results, and publication bias. In addition, several factors can increase our confidence in an estimate of effect. GRADE provides a systematic approach for considering and reporting each of these factors. GRADE separates the process of assessing quality of evidence from the process of making recommendations. Judgments about the strength of a recommendation depend on more than just the quality of evidence. Copyright © 2011 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

              New clinical, laboratory and experimental insights, since the 1999 publication of the Sapporo preliminary classification criteria for antiphospholipid syndrome (APS), had been addressed at a workshop in Sydney, Australia, before the Eleventh International Congress on antiphospholipid antibodies. In this document, we appraise the existing evidence on clinical and laboratory features of APS addressed during the forum. Based on this, we propose amendments to the Sapporo criteria. We also provide definitions on features of APS that were not included in the updated criteria.
                Bookmark

                Author and article information

                Journal
                Autoimmun Rev
                Autoimmunity reviews
                1873-0183
                1568-9972
                Sep 2014
                : 13
                : 9
                Affiliations
                [1 ] Graham Hughes Lupus Research Laboratory, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, London, UK. Electronic address: maria.bertolaccini@kcl.ac.uk.
                [2 ] Department of Internal Medicine II, Hokkaido University School of Medicine, Sapporo, Japan.
                [3 ] Department of Clinical and Experimental Sciences, University of Brescia, Italy; Rheumatology and Clinical Immunology Unit, Spedali Civili, Brescia, Italy.
                [4 ] Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Italy; Experimental Laboratory of Immunorheumatology, Istituto Auxologico Italiano, Milan, Italy.
                [5 ] Department of Physiology, Favaloro University, Division of Hematology, Thrombosis and Haemostasis, University Hospital, Favaloro Foundation, Buenos Aires, Argentina.
                [6 ] Department of Clinical Chemistry and Haematology, University Medical Center, Utrecht, The Netherlands.
                [7 ] INOVA Diagnostics, San Diego, CA, USA.
                [8 ] Service de Médecine Interne, Hôpital Claude-Huriez, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.
                [9 ] Experimental Laboratory of Immunorheumatology, Istituto Auxologico Italiano, Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Italy.
                [10 ] Clinical Coagulation Laboratory, Laboratory-Based Research, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
                [11 ] Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
                [12 ] Centre for Rheumatology, Division of Medicine University College London, London, UK.
                [13 ] Division of Rheumatology, Allergy, and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Thurston Arthritis Research Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
                [14 ] Graham Hughes Lupus Research Laboratory, Lupus Research Unit, The Rayne Institute, King's College London School of Medicine, London, UK.
                [15 ] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
                [16 ] Associated Regional and University Pathologists (ARUP) Institute for Clinical and Experimental Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
                [17 ] Antiphospholipid Standardization Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
                Article
                S1568-9972(14)00120-7
                10.1016/j.autrev.2014.05.001
                24824074
                830e1e76-2f9f-4e6e-b152-522be1807e7f
                Copyright © 2014 Elsevier B.V. All rights reserved.
                History

                Antiprothrombin antibodies,Domain I,IgA,Lupus anticoagulant,Risk,aCL

                Comments

                Comment on this article